CA2112360A1 - Bicyclic fibrinogen antagonists - Google Patents

Bicyclic fibrinogen antagonists

Info

Publication number
CA2112360A1
CA2112360A1 CA002112360A CA2112360A CA2112360A1 CA 2112360 A1 CA2112360 A1 CA 2112360A1 CA 002112360 A CA002112360 A CA 002112360A CA 2112360 A CA2112360 A CA 2112360A CA 2112360 A1 CA2112360 A1 CA 2112360A1
Authority
CA
Canada
Prior art keywords
amino
oxo
tetrahydro
phenyl
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002112360A
Other languages
English (en)
French (fr)
Inventor
William Edward Bondinell
James Francis Callahan
William Francis Huffman
Richard Mcculloch Keenan
Thomas Wen-Fu Ku
Kenneth Allen Newlander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2112360A1 publication Critical patent/CA2112360A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/10—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002112360A 1991-06-28 1992-06-26 Bicyclic fibrinogen antagonists Abandoned CA2112360A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72300991A 1991-06-28 1991-06-28
US07/723,009 1991-06-28
PCT/US1992/005463 WO1993000095A2 (en) 1991-06-28 1992-06-26 Bicyclic fibrinogen antagonists

Publications (1)

Publication Number Publication Date
CA2112360A1 true CA2112360A1 (en) 1993-12-23

Family

ID=24904429

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002112360A Abandoned CA2112360A1 (en) 1991-06-28 1992-06-26 Bicyclic fibrinogen antagonists

Country Status (15)

Country Link
US (1) US5693636A (enExample)
EP (1) EP0593603B1 (enExample)
JP (1) JP3497164B2 (enExample)
KR (1) KR940701259A (enExample)
AT (1) ATE228115T1 (enExample)
AU (1) AU666318B2 (enExample)
CA (1) CA2112360A1 (enExample)
DE (1) DE69232854T2 (enExample)
ES (1) ES2190428T3 (enExample)
IE (1) IE922087A1 (enExample)
NZ (1) NZ243326A (enExample)
PT (1) PT100631B (enExample)
TW (1) TW218018B (enExample)
WO (1) WO1993000095A2 (enExample)
ZA (1) ZA924760B (enExample)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017877A (en) * 1990-04-06 2000-01-25 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5780303A (en) * 1990-04-06 1998-07-14 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6521594B1 (en) 1990-04-06 2003-02-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US6019958A (en) * 1991-02-08 2000-02-01 Diatide, Inc. Technetium-99m labeled peptides for imaging inflammation
ATE188387T1 (de) * 1991-02-08 2000-01-15 Diatide Inc Technetium-99m markierte polypeptide zur bildformung
US5645815A (en) 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US5736122A (en) * 1991-02-08 1998-04-07 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
DE69232854T2 (de) * 1991-06-28 2003-09-04 Smith-Kline Beecham Corp., King Of Prussia Bizyklische fibrinogenantagonisten
US5939412A (en) * 1992-06-26 1999-08-17 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5663166A (en) * 1991-10-18 1997-09-02 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
SG63579A1 (en) * 1992-12-21 1999-03-30 Smithkline Beecham Corp Bicyclic fibrinogen antagonists
US5441952A (en) * 1993-04-05 1995-08-15 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2363780C (en) * 1993-04-08 2003-01-07 Diatide, Inc. Radiolabeled compounds for thrombus imaging
AU6909194A (en) * 1993-05-14 1994-12-12 Board Of Regents, The University Of Texas System Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicyclic compounds and pharmaceutical compositions containing them
US6137002A (en) 1993-07-22 2000-10-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US6448269B1 (en) 1993-07-22 2002-09-10 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US6403578B1 (en) 1993-12-21 2002-06-11 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
MA23420A1 (fr) * 1994-01-07 1995-10-01 Smithkline Beecham Corp Antagonistes bicycliques de fibrinogene.
JPH10504807A (ja) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗剤
PL318199A1 (en) * 1994-06-29 1997-05-26 Smithkline Beecham Corp Antagonists of vitronectin receptors
US6458784B1 (en) * 1994-06-29 2002-10-01 Smithkline Beecham Corporation Vitronectin receptor antagonists
JPH10504825A (ja) * 1994-08-22 1998-05-12 スミスクライン・ビーチャム・コーポレイション 二環式化合物
EP0796252A4 (en) * 1994-12-09 1998-02-04 Smithkline Beecham Corp BICYCLIC FIBRINOGEN ANTAGONISTS
WO1996018602A1 (en) * 1994-12-13 1996-06-20 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
DE19516483A1 (de) * 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
JP2000502708A (ja) * 1995-12-29 2000-03-07 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗物質
ZA9610853B (en) 1995-12-29 1998-04-06 Smithkline Beecham Corp Processes and intermediates for preparing pharmaceuticals.
WO1998004247A1 (en) * 1996-07-25 1998-02-05 Biogen, Inc. Cell adhesion inhibitors
US6686350B1 (en) 1996-07-25 2004-02-03 Biogen, Inc. Cell adhesion inhibitors
US5693641A (en) * 1996-08-16 1997-12-02 Berlex Laboratories Inc. Bicyclic pyrimidine derivatives and their use as anti-coagulants
TR199900480T2 (xx) 1996-09-03 1999-06-21 Smithkline Beecham Corporation Kristalin farmas�tik �r�n.
US20030125317A1 (en) * 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653645A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
IL130580A0 (en) * 1996-12-27 2000-06-01 Smithkline Beecham Plc Enzymatic resolution of benzodiazepine-acetic acid esters with a lipase
CN1328278C (zh) * 1997-07-31 2007-07-25 宇部兴产株式会社 N－酰基氨基酸酰胺化合物及其制造中间体
US6100254A (en) * 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
AU1687699A (en) * 1997-12-25 1999-07-19 Yamanouchi Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivatives
US6197794B1 (en) 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
KR20010082515A (ko) 1998-02-17 2001-08-30 우에노 도시오 아미디노 유도체 및 그 유도체를 유효 성분으로서함유하는 약제
WO1999043642A1 (en) 1998-02-26 1999-09-02 Celltech Therapeutics Limited Phenylalanine derivatives as inhibitors of alpha4 integrins
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
JP2003504301A (ja) 1998-04-01 2003-02-04 ブリストル−マイヤーズ スクイブ ファーマ カンパニー インテグリンアンタゴニスト
GB9811159D0 (en) 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
GB9812088D0 (en) 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6974878B2 (en) * 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
US6204282B1 (en) 1998-11-30 2001-03-20 Schering Corporation Benzimidazole compounds that are vitronectin receptor antagonists
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
AU3894800A (en) * 1999-03-23 2000-10-09 Axys Pharmaceuticals, Inc. Solid phase synthesis of benzodiazepine diones
GB9908662D0 (en) * 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel process for preparing benzodiazepines
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
AU5826100A (en) 1999-07-13 2001-01-30 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
WO2001007036A1 (en) 1999-07-21 2001-02-01 American Home Products Corporation BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
EP1229913A4 (en) 1999-11-18 2005-01-19 Antexpharma Inc SUBSTITUTED 1-BENZAZEPINE AND THEIR DERIVATIVES
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
EP1332132B1 (en) 2000-04-17 2007-10-10 UCB Pharma, S.A. Enamine derivatives as cell adhesion molecules
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
JP2004502762A (ja) 2000-07-07 2004-01-29 セルテック　アール　アンド　ディ　リミテッド 二環性ヘテロ芳香環を含有するインテグリンアンタゴニストとしてのスクエア酸誘導体
WO2002010136A1 (en) 2000-08-02 2002-02-07 Celltech R & D Limited 3-substituted isoquinolin-1-yl derivatives
KR101159061B1 (ko) 2001-10-22 2012-06-22 더 스크립스 리서치 인스티튜트 항체 표적화 화합물
WO2004052364A1 (en) 2002-12-06 2004-06-24 The Trustees Of Boston University METHODS FOR SUSTAINING eNOS ACTIVITY
US7928143B2 (en) * 2003-10-03 2011-04-19 Ono Pharmaceutical Co., Ltd. Method for preventing and/or treating neurodegenerative diseases
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
JP2009512443A (ja) * 2005-10-20 2009-03-26 ザ スクリップス リサーチ インスチチュート 免疫染色及び免疫標的化のためのＦｃ標識化
EP2395992A2 (en) 2009-02-10 2011-12-21 The Scripps Research Institute Chemically programmed vaccination
SMT201700456T1 (it) 2009-07-27 2017-11-15 Gilead Sciences Inc Composti eterociclici fusi come modulatori dei canali ionici
JP5858586B2 (ja) 2010-07-02 2016-02-10 ギリアード サイエンシーズ， インコーポレイテッド イオンチャネルモジュレーターとしての縮合複素環式化合物
TWI577670B (zh) 2011-05-10 2017-04-11 基利科學股份有限公司 充當離子通道調節劑之稠合雜環化合物
NO3175985T3 (enExample) 2011-07-01 2018-04-28
AU2015224425B2 (en) * 2011-07-01 2017-02-09 Gilead Sciences, Inc. Fused benzoxazepinones as ion channel modulators
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
EP2708535A1 (en) 2012-05-11 2014-03-19 Les Laboratoires Servier Agents for treating disorders involving modulation of ryanodine receptors
US10183940B2 (en) * 2014-11-14 2019-01-22 Boehringer Ingelheim International Gmbh Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists
CN105348148B (zh) * 2015-11-30 2017-12-26 山东新华制药股份有限公司 制备达比加群酯中间体缩合物的杂质的草酸盐的方法
EP3521269A1 (en) 2018-02-06 2019-08-07 Clariant Plastics & Coatings Ltd Process for preparation of 1-nitrobenzene-2-alkyloxycarbonyl-5-carboxylic acid
CN110845308A (zh) * 2019-10-24 2020-02-28 扬州工业职业技术学院 一种辣椒素的制备工艺
CN113444009B (zh) * 2021-07-28 2023-08-01 珠海润都制药股份有限公司 一种坎地沙坦酯中间体母液的回收方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1592552A (en) * 1976-12-10 1981-07-08 Inst Nat Sante Rech Med Pseudopeptides used as medicaments
LU77316A1 (enExample) * 1977-05-11 1979-01-19
HU179018B (en) * 1978-10-19 1982-08-28 Gyogyszerkutato Intezet Process for producing new 5h-2,3-benzodiazepine derivatives
CA1145333A (en) * 1980-02-08 1983-04-26 Quirico Branca Benzodiazepine derivatives
CA1157855A (en) * 1980-07-31 1983-11-29 Albert E. Fischli Benzodiazepine derivatives
CA1163266A (en) * 1980-07-31 1984-03-06 Albert E. Fischli Benzodiazepine derivatives
NL8005133A (nl) * 1980-09-12 1982-04-01 Duphar Int Res Fenylpiperazinederivaten met antiagressieve werking.
NZ204130A (en) * 1982-05-12 1986-03-14 Hoffmann La Roche Bicyclic heterocyclic compounds and pharmaceutical compositions
US5059688A (en) * 1982-06-14 1991-10-22 Hoechst-Roussel Pharmaceuticals Inc. 1-aryloxy-2,3,4,5-tetrahydro-3-benzazepine preparation
DE3418271A1 (de) * 1984-05-17 1985-11-21 Dr. Karl Thomae Gmbh, 7950 Biberach Neue benzazepinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US4820834A (en) * 1984-06-26 1989-04-11 Merck & Co., Inc. Benzodiazepine analogs
EP0204349A3 (de) * 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ES2052595T3 (es) * 1986-12-15 1994-07-16 Inst Nat Sante Rech Med Nuevos derivados peptidicos y su aplicacion en especial en terapeutica.
DE3702755A1 (de) * 1987-01-30 1988-08-11 Hoechst Ag 3,5-di-tert.-butyl-4-hydroxybenzoesaeureamid, verschiedene von dessen derivaten, verfahren zur herstellung dieser verbindungen, die sie enthaltenden arzneimittel und ihre verwendung
EP0731110A1 (en) * 1987-12-10 1996-09-11 La Jolla Cancer Research Foundation Methods for the production of conformationally stabilized cell adhesion peptides
DK107688D0 (da) * 1988-03-01 1988-03-01 Novo Industri As Carbaminsyreestere af substituerede 7-hydroxy-2,3,4,5-tetrahydro-1h-3-benzazepiner
ZW6189A1 (en) * 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
US4902684A (en) * 1988-06-20 1990-02-20 E. R. Squibb & Sons, Inc. Benzazepine and benzothiazepine derivatives
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5084466A (en) * 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
DK0389189T3 (da) * 1989-03-23 1994-06-20 Pfizer Diazepin antiallergimidler
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
IL99539A0 (en) * 1990-09-27 1992-08-18 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
NZ239876A (en) * 1990-09-27 1993-12-23 Merck & Co Inc Glycyl-b-alanine derivatives and pharmaceutical compositions thereof.
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
JPH06502643A (ja) * 1990-11-01 1994-03-24 スミスクライン・ビーチャム・コーポレイション フィブリノーゲン拮抗剤としてのγ−ターンペプチド模倣化合物
WO1992009297A1 (en) * 1990-11-30 1992-06-11 Smithkline Beecham Corporation Hiv protease inhibitors
CA2066104C (en) * 1991-04-19 2003-05-27 Hidenori Ogawa Benzazepine derivatives as vasopressin antagonists
EP0523845A3 (en) * 1991-06-14 1993-11-18 Merck & Co Inc New benzodiazepine analogs
DE69232854T2 (de) * 1991-06-28 2003-09-04 Smith-Kline Beecham Corp., King Of Prussia Bizyklische fibrinogenantagonisten
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
US5149699A (en) * 1991-10-24 1992-09-22 American Home Products Corporation Substituted pyridopyrimidines useful as antgiotensin II antagonists
US5241065A (en) * 1992-02-25 1993-08-31 Schering Corporation 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity
ATE163927T1 (de) * 1992-11-09 1998-03-15 Knoll Ag 1,4-benzothiazepine verwendbar als neurologische mittel
SG63579A1 (en) * 1992-12-21 1999-03-30 Smithkline Beecham Corp Bicyclic fibrinogen antagonists
US5493020A (en) * 1993-07-29 1996-02-20 Genentech, Inc. Tricyclic inhibitors of the GPIIb IIIa receptor

Also Published As

Publication number Publication date
PT100631A (pt) 1993-09-30
ES2190428T3 (es) 2003-08-01
EP0593603A1 (en) 1994-04-27
AU2271192A (en) 1993-01-25
DE69232854T2 (de) 2003-09-04
US5693636A (en) 1997-12-02
KR940701259A (ko) 1994-05-28
TW218018B (enExample) 1993-12-21
WO1993000095A2 (en) 1993-01-07
WO1993000095A3 (en) 1993-02-18
IE922087A1 (en) 1992-12-30
JPH06509074A (ja) 1994-10-13
AU666318B2 (en) 1996-02-08
EP0593603A4 (en) 1994-03-07
PT100631B (pt) 1999-06-30
EP0593603B1 (en) 2002-11-20
ZA924760B (en) 1993-03-31
DE69232854D1 (de) 2003-01-02
JP3497164B2 (ja) 2004-02-16
ATE228115T1 (de) 2002-12-15
NZ243326A (en) 1995-10-26

Similar Documents

Publication Publication Date Title
CA2112360A1 (en) Bicyclic fibrinogen antagonists
EP0674623B1 (en) Bicyclic fibrinogen antagonists
US5602145A (en) Bicyclic fibrinogen antagonists
CA2096460C (en) Dual action inhibitors
US5939412A (en) Bicyclic fibrinogen antagonists
US6117910A (en) Bicyclic fibrinogen antagonists
US6069143A (en) Fibrinogen receptor antagonists
WO1993009133A1 (en) C8-cyclic peptidomimetics as fibrinogen antagonists
WO1996017833A1 (en) Bicyclic fibrinogen antagonists
US5726192A (en) Platelet aggregation inhibiting compounds
US6028087A (en) Platelet aggregation inhibiting compounds
US6403578B1 (en) Bicyclic fibrinogen antagonists
WO1994022440A1 (en) Bicyclic compounds which inhibit platelet aggregation
WO1994022444A1 (en) Tricyclic compounds for inhibiting platelet aggregation
EP0677041A1 (en) Chemical compounds
AU4380301A (en) Bicyclic fibrinogen antagonists
NZ260616A (en) Platelet aggregation inhibitors optionally containing a gly-asp unit and pharmaceutical compositions

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued